Biogen Idec Exclusively Licenses Isis Antisense Tech for Neurological Diseases | GenomeWeb

Isis Pharmaceuticals this week announced that it had formed a strategic alliance with Biogen Idec to develop antisense-based treatments for neurological disorders.

Under the terms of the six-year arrangement, Biogen Idec will have the exclusive rights to use Isis' antisense technology to develop drugs for neurological diseases. Isis will receive $100 million upfront and is eligible to receive milestones, license fees, and royalties on all products developed under the arrangement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.